Literature DB >> 10078740

Creatine monohydrate increases strength in patients with neuromuscular disease.

M Tarnopolsky1, J Martin.   

Abstract

Creatine monohydrate has been shown to increase strength in studies of young healthy subjects and in a few studies with patients. Creatine monohydrate (10 g daily for 5 days to 5 g daily for 5 days) was administered to patients with neuromuscular disease in a pilot study (Study 1; n = 81), followed by a single-blinded study (Study 2; n = 21). Body weight, handgrip, dorsiflexion, and knee extensor strength were measured before and after treatment. Creatine administration increased all measured indices in both studies. Short-term creatine monohydrate increased high-intensity strength significantly in patients with neuromuscular disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078740     DOI: 10.1212/wnl.52.4.854

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

Review 2.  Creatine supplementation in health and disease: what is the evidence for long-term efficacy?

Authors:  Wim Derave; Bert O Eijnde; Peter Hespel
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

3.  Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans.

Authors:  Mark Tarnopolsky; Gianni Parise; Min-Hua Fu; Andrea Brose; Andrew Parshad; Oliver Speer; Theo Wallimann
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 4.  Creatine for treating muscle disorders.

Authors:  Rudolf A Kley; Mark A Tarnopolsky; Matthias Vorgerd
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

5.  Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Authors:  R J Ferrante; O A Andreassen; B G Jenkins; A Dedeoglu; S Kuemmerle; J K Kubilus; R Kaddurah-Daouk; S M Hersch; M F Beal
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

Review 6.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

7.  Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.

Authors:  P Hespel; B Op't Eijnde; M Van Leemputte; B Ursø; P L Greenhaff; V Labarque; S Dymarkowski; P Van Hecke; E A Richter
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

8.  Creatine Supplementation Supports the Rehabilitation of Adolescent Fin Swimmers in Tendon Overuse Injury Cases.

Authors:  Imre Juhasz; Judit Plachy Kopkane; Pal Hajdu; Gabor Szalay; Bence Kopper; Jozsef Tihanyi
Journal:  J Sports Sci Med       Date:  2018-05-14       Impact factor: 2.988

9.  Striking improvement of muscle strength under creatine therapy in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.

Authors:  G C Korenke; R J A Wanders; F Hanefeld
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 10.  Therapeutics in duchenne muscular dystrophy.

Authors:  Jonathan B Strober
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.